US Pharma MarketingThe post MASH therapy enters a more competitive era appeared first on Clinical Trials Arena.
MASH therapy enters a more competitive era
When the FDA approved Madrigal's Rezdiffra in 2024, it was the first marketed drug ever for MASH, which affects millions of American adults. Rezdiffra is no longer the only option; it is the incumbent to beat, and it is being approached from two different mechanistic directions at once. Semaglutide’s approval for MASH last August made it a two-drug market and, more importantly, invited the entire GLP-1 space into hepatology. Credit: oleschwander / Shutterstock.com. For much of the last two years, there has only been one real way to treat metabolic dysfunction-associated steatohepatitis (MASH). When the US Food and Drug Administration…
When the FDA approved Madrigal's Rezdiffra in 2024, it was the first marketed drug ever for MASH, which affects millions of American adults.
Source: Clinical Trials Arena